Onset Therapeutics expands its sales force to create nationwide presence

Jan 28 2010

Onset Therapeutics LLC, a specialty pharmaceutical company focused in dermatology, today announced that the Company’s recent growth and future opportunities have facilitated an expansion of its field sales organization to cover more than twenty-five additional major metropolitan areas. The expansion is a direct result of the success of two recently launched dermatologic products and the Company’s robust product pipeline that includes both near term and mid-term product candidates.

“The successful launch of our two latest products in 2009 has enabled us to continue to expand the breadth and depth of our sales force to create our first nationwide presence”

The Company has significant internal product development and manufacturing capabilities which have led to the development of the Company’s proprietary Delevo® Foam technology. Delevo® Foam is an emollient, non-alcohol based foam vehicle that is incorporated into a number of the Company’s current and future product offerings, including the recently launched products, Hylatopic® and BenzEFoam™.

Hylatopic® Emollient Foam, a unique, non-steroidal prescription product indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including atopic dermatitis, allergic contact dermatitis and radiation dermatitis, received FDA clearance in the spring of 2009 and was launched by the Company in July 2009.

BenzEFoam™ (benzoyl peroxide) 5.3% Emollient Foam, is the first prescription foam formulation of benzoyl peroxide. BenzEFoam™ Emollient Foam is indicated for the topical treatment of mild to moderate acne vulgaris and was launched in October 2009. BenzEFoam™ spreads easily over the extensive skin areas of the chest and back, where body acne symptoms most often occur. BenzEFoam™ is formulated to address the needs of patients with body acne and offers an ideal treatment option for them.

The Company also announced the acceptance of an Investigational New Drug (IND) application by the US Food and Drug Administration (FDA) for COL-177, which is currently in clinical development for the topical treatment of acne vulgaris. COL -177 utilizes the Company’s Delevo® Foam Technology to deliver the active ingredient in an emollient foam vehicle that is intended to enhance patient acceptability and tolerability which may result in increased patient compliance.

“The successful launch of our two latest products in 2009 has enabled us to continue to expand the breadth and depth of our sales force to create our first nationwide presence,” states Doug Abel, General Manager of Onset Therapeutics. “We are excited about our strong product pipeline, as we are confident that our pipeline products will strengthen our dermatologic product portfolio over the long term.”